Botox, Dysport, Xeomin, Daxxify: What Actually Differs When the Molecule Is Nearly the Same

Six brands, one mechanism, stated once

The United States now has six FDA-approved botulinum toxin type A products for cosmetic use: Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA), Daxxify (daxibotulinumtoxinA) and Letybo (letibotulinumtoxinA), the most recent, approved in February 2024 for glabellar lines.

All six do the same thing. Botulinum toxin type A cleaves SNAP-25, a protein required for acetylcholine-containing vesicles to fuse with the nerve terminal membrane. Without that fusion, acetylcholine is not released into the neuromuscular junction, the muscle fibre does not receive the signal to contract, and the dynamic line that contraction produces does not form. The effect wears off as new nerve terminals sprout and the junction is restored.

That paragraph covers every product on the list. There is no brand whose mechanism differs, no brand that works on the skin rather than the muscle, and no brand that does something to collagen.

What differs is the packaging around that identical event: the size and purity of the protein complex, the stabilising excipient, the potency assay used to define a unit, and — in one case — a duration claim. Those differences are real. They are also small, and the ones the marketing emphasises are largely not the ones that matter.

Units are not a currency, and this is where people get overcharged

This is the most immediately useful thing in the article, so it goes first among the differences.

A 'unit' of botulinum toxin is not a standard measure like a milligram. It is a potency figure defined by each manufacturer's own biological assay, and those assays are not interchangeable. A Dysport unit and a Botox unit are different quantities of biological effect, by design.

The conversion between Dysport and Botox is conventionally quoted around 3:1 — three Dysport units to one Botox unit — though a lower ratio has been argued for. A double-blind randomised study in cervical dystonia found Dysport non-inferior to Botox on safety and efficacy at a conversion factor of 2.5:1, and the appropriate ratio remains a live clinical discussion.

The consumer consequence is direct. A clinic advertising a low per-unit price for Dysport is advertising a smaller unit, and a glabellar treatment that takes twenty units of one product might take fifty of another for the same clinical effect. Comparing per-unit prices across brands is not comparison shopping; it is a category error that clinics are under no obligation to correct.

Ask for the price per treatment area rather than per unit. If a clinic will only quote per unit, ask how many units of that specific product they typically use for that area, and multiply. This single question does more to protect you financially than any amount of brand research.

Onset and spread: smaller and less brand-specific than claimed

The most commonly repeated distinction is that Dysport starts working faster and spreads more widely, making it suited to large areas like the forehead and less suited to precise work.

The onset half has reasonable clinical support and is a genuine practical consideration if you have an event in four days rather than ten.

The diffusion half deserves more scrutiny than it usually gets. The traditional explanation was that the accessory or complexing proteins wrapped around the neurotoxin affected how far it travelled from the injection point. That explanation does not hold up well: comparisons of conventional preparations against the complexing-protein-free formulation strongly suggest that complexing proteins do not affect diffusion of the active neurotoxin. And a study comparing Dysport to Botox at a 2.5:1 ratio on the upper frontalis and lateral periorbital area found no diffusion difference between them.

If the molecule is not driving spread, what is? Dose, dilution volume, injection depth, injection speed and the number of points across which a given dose is distributed. Every one of those is a decision the injector makes, not a property of the vial.

Which reframes the whole 'Dysport spreads more' folk wisdom as, at least partly, an observation about how clinics conventionally reconstitute and dose it. That is worth knowing, because it moves the variable from something you choose at the counter to something you should be discussing with the person injecting you.

Xeomin's real differentiator, and why it matters least where it's marketed most

One product does have a formulation difference with a coherent biological rationale behind it, and it is not the one with the biggest advertising budget.

Xeomin is the licensed botulinum neurotoxin preparation free of complexing proteins — a purified toxin with the accessory proteins and biologically inactive fragments removed, and a markedly reduced total clostridial protein load.

The rationale is immunogenicity. Complexing proteins, particularly the hemagglutinin component, may act as adjuvants that enhance the immune response to an injection. Removing them plausibly reduces antigenicity, and the evidence is consistent with that: animal work suggests low antigenicity, and long-term clinical studies report treatment without induction of neutralising antibodies. Patients with cervical dystonia who had become resistant to complexing-protein-containing preparations have shown clinical improvement after switching.

Here is the honest calibration, which cuts against how this gets sold in aesthetic settings. Secondary non-response driven by neutralising antibodies is a real and serious problem — in therapeutic neurology, where patients receive hundreds of units repeatedly for spasticity or dystonia. Cosmetic dosing is a fraction of that, at longer intervals, and treatment failure from neutralising antibodies is uncommon in that population.

So the immunogenicity advantage is genuine and it matters most for the patient least likely to be reading a cosmetic article: the high-dose therapeutic user. For someone treating glabellar lines twice a year, it is a reasonable tiebreaker and not a reason to switch. Saying that clearly is more respectful of a reader than either overselling it or dismissing it.

Daxxify's duration claim, read off the actual endpoint

Daxxify arrived on a duration promise, and duration is the one axis where a genuine product difference would matter enormously. So it deserves the closest reading.

The formulation is legitimately novel: a 150-kDa botulinum toxin type A paired with a proprietary stabilising excipient peptide in place of the human serum albumin used in conventional preparations. The peptide is the differentiator, and the hypothesis is that it improves the toxin's association with the target tissue.

The pivotal evidence comes from SAKURA 1 and SAKURA 2, two multicentre, randomised, double-blind, placebo-controlled phase 3 studies in moderate-to-severe glabellar lines, using 40 units. Pooled analysis reported a prolonged duration of response, with median duration of none-or-mild glabellar line severity of 24.0 weeks in one study and 23.9 in the other.

Read that endpoint precisely, because the marketing rounds it into something it does not say. 'Median duration of none-or-mild severity' means half of participants still had none-or-mild lines at around 24 weeks. It is not the median time until movement fully returns, it is not a guarantee of six months, and a median means half the participants fell below it. Some patients report duration no better than conventional toxins, and that is entirely consistent with the trial data rather than evidence against it.

So: the trials are real, well designed, and support a longer median duration than the historical three-to-four-month expectation. What they do not support is 'lasts twice as long', which is the version most people have heard. If duration is your priority, Daxxify is a defensible choice with published evidence — priced accordingly, and with the standard caveat that a longer-acting neuromodulator also means a longer wait if you dislike the result, since there is no reversal agent for any product in this class.

The variable that actually decides your result

Here is the conclusion that all of the above is in service of: the spread between a good and a bad result from the same brand is larger than the spread between brands.

Every outcome people fear or want is a placement and dosing outcome. A heavy, dropped brow comes from treating the frontalis too low or too heavily in someone using it to hold the brow up. A peaked 'spock' brow comes from uneven lateral frontalis treatment. Ptosis comes from product reaching the levator. A frozen, expressionless forehead comes from dose, not from a vial. And a natural result — movement preserved, lines softened — comes from someone who understood which muscles that particular face uses and how it compensates.

None of that is on the label.

So the practical protocol inverts the usual order. Choose the injector; let them choose the toxin. A practitioner who works with one product daily and knows its dosing intimately will outperform one using your preferred brand occasionally.

Questions worth asking, and our derm visit prep tool will assemble the rest: how many treatments do you do per week in this specific area; can I see your own before-and-after photographs taken at two weeks rather than on the day; what is your approach if I develop a dropped brow or lid; and what is the price for this area rather than per unit. A good injector answers all four without defensiveness — and if brand-trust reasoning is what brought you here, ↗how much a brand's own labelling is worth is the same question in a different aisle.

One last thing worth understanding about scope. Neuromodulators treat dynamic lines — the ones that appear when you move. A line that is visible at complete rest is an etched, static line, and it is a dermal problem rather than a muscular one. Softening the movement will slow it deepening, but the existing crease responds to remodelling: a retinoid such as CeraVe Resurfacing Retinol Serum, consistent photoprotection, and time. ↗The retinol page covers the timescale, and ↗peptides — including the topical products built on The Ordinary Argireline Solution 10%, which is marketed on a superficially similar mechanism at a completely different order of magnitude — are the softer adjunct. After treatment, keep it simple: Avène Cicalfate Restorative Protective Cream or Eucerin Advanced Repair Cream over injection points, and nothing active for a day.